Exited position

David Abrams’s Biogen Inc (BIIB) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Abrams Capital Management, L.P.Verified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2007Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares700.00KHighest verified quarter-end share count
Quarters reported1Verified quarters with shares above zero
What happened?

Abrams Capital Management, L.P. first reported Biogen Inc in Q2 2007. The latest verified relationship event shows that Abrams Capital Management, L.P. sold the entire position in Q3 2007, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2007
Sold the entire position−700.00K shares · No shares reported at quarter-end
Q2 2007
New position+700.00K shares · 700.00K shares reported
Filing context

Quarter-end price $53.00 · Estimated holding basis $53.00

Portfolio importance

How important was Biogen Inc in Abrams Capital Management, L.P.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight1.5%Q2 2007
Last reported rank#17of 21 reported positions
Peak portfolio weight1.5%Q2 2007
Best historical rank#17Q2 2007
At peak importanceQ2 2007
BIIB
1.5%
Largest holding
11.2%
Cross-investor discovery

Who else owns Biogen Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Explore Biogen Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$216.012026-09-16

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

This tracker follows Abrams Capital Management, L.P.’s Form 13F disclosures, not David Abrams’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.